Loading...
The future of treatment for patients with relapsed/refractory multiple myeloma: The Future of Proteasome Inhibitors in Relapsed/Refractory Multiple Myeloma
The ubiquitin-proteasome pathway was first validated as a target for cancer therapy with the demonstration of the activity of the boronic acid proteasome inhibitor bortezomib against relapsed and relapsed/refractory multiple myeloma. Another generation of proteasome inhibitors is now entering the cl...
Na minha lista:
| Hovedforfatter: | |
|---|---|
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
2011
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4163602/ https://ncbi.nlm.nih.gov/pubmed/25188482 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|